Patents by Inventor Stuart L. Bursten
Stuart L. Bursten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7595341Abstract: The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ?-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.Type: GrantFiled: April 30, 2008Date of Patent: September 29, 2009Assignees: Resolvyx Pharmacuticals, Inc., The Brigham and Women's HospitalInventors: Daniel W. Goodman, Michael R. Hanley, Stuart L. Bursten, Charles N. Serhan
-
Publication number: 20080207753Abstract: The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ?-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.Type: ApplicationFiled: April 30, 2008Publication date: August 28, 2008Applicants: Resolvyx Pharmaceuticals, Inc., The Brigham and Women's Hospital, Inc.Inventors: Daniel W. Goodman, Michael R. Hanley, Stuart L. Bursten, Charles N. Serhan
-
Patent number: 7378444Abstract: The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ?-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.Type: GrantFiled: June 13, 2003Date of Patent: May 27, 2008Assignees: Brigham and Women's Hospital, Inc., Resolvyx Pharmaceuticals, Inc.Inventors: Daniel W. Goodman, Michael R. Hanley, Stuart L. Bursten, Charles N. Serhan
-
Publication number: 20040044050Abstract: The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 &ohgr;-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.Type: ApplicationFiled: June 13, 2003Publication date: March 4, 2004Inventors: Daniel W. Goodman, Michael R. Hanley, Stuart L. Bursten
-
Publication number: 20030216414Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).Type: ApplicationFiled: May 9, 2003Publication date: November 20, 2003Applicant: Cell Therapeutics,Inc.Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
-
Patent number: 6638938Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).Type: GrantFiled: December 12, 1994Date of Patent: October 28, 2003Assignee: Cell Therapeutics, Inc.Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
-
Patent number: 5929081Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease andType: GrantFiled: June 7, 1995Date of Patent: July 27, 1999Assignee: Cell Therapeutics Inc.Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
-
Patent number: 5859017Abstract: In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.Type: GrantFiled: April 1, 1994Date of Patent: January 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: Elisa Eiseman, Emer Clarke, Jack W. Singer, Stuart L. Bursten
-
Patent number: 5859018Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease andType: GrantFiled: June 7, 1995Date of Patent: January 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
-
Patent number: 5856331Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).Type: GrantFiled: October 10, 1997Date of Patent: January 5, 1999Assignee: Cell Therapeutics, Inc.Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
-
Patent number: 5856115Abstract: There is disclosed a method for screening for inhibitors of cellular second messenger signaling regulated by lysophosphatidic acid acyl transferase (LPAAT) and phosphatidic acid phosphohydrolase (PAPH), which method comprises contacting target cells or appropriate subcullular elements under appropriate conditions of stimulation with a candidate drug and assessing the levels of the relevant subsets of phosphatidic acid (PA) and diacylglycerol (DAG) in the presence and absence of the candidate drug.Type: GrantFiled: February 14, 1994Date of Patent: January 5, 1999Assignee: Fred Hutchinson Cancer Research CenterInventors: James A. Bianco, Stuart L. Bursten, Jack W. Singer
-
Method for treating diseases mediated by cellular proliferation in response to PDGF,EGF,FGF and VEGF
Patent number: 5795898Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease andType: GrantFiled: June 7, 1995Date of Patent: August 18, 1998Assignee: Cell Therapeutics, Inc.Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer -
Patent number: 5780237Abstract: There is disclosed a diagnostic assay for adult respiratory distress syndrome (ARDS), sepsis, multiple organ dysfunction (MOD) and systemic inflammatory response syndrome (SIRS), comprising (a) measuring the amount of selected unsaturated free fatty acids (FFAs) and saturated FFAs in a body fluid, and (b) determining a ratio value comprising the sum of the unsaturated FFAs divided by the sum of the saturated FFAs. There is further disclosed a diagnostic assay for ARDS, sepsis, MOD and SIRS, comprising (a) measuring the amount of 9- or 13-hydroxyoctadecadienoic acid (HODE) and 5-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HETE) in a body fluid, and (b) determining a ratio value of HETE and HODE.Type: GrantFiled: October 12, 1994Date of Patent: July 14, 1998Assignee: Cell Therapeutics, Inc.Inventors: Stuart L. Bursten, David A. Federighi
-
Patent number: 5773300Abstract: There is disclosed a diagnostic assay for determining the presence of a neoplasia or a tumor burden in a mammal comprising (a) measuring the amount of unsaturated free fatty acids (FFAs) linolenate and arachidonate in a body fluid, and (b) determining a ratio value comprising the sum of linolenate and the sum of arachidonate.Type: GrantFiled: April 23, 1997Date of Patent: June 30, 1998Assignee: Cell Therapeutics, Inc.Inventors: David A. Federighi, Stuart L. Bursten
-
Patent number: 5585380Abstract: The specification discloses methods for modulating cellular metabolism in a subject, modulating being desirable to mitigate a condition of the subject. Disclosed methods include processes for administering to said subject an effective amount of a compound of the formula ##STR1## wherein one and only one of R.sup.1 and R.sup.3 is a straight-chain or branched-chain .omega.-hydroxyalkyl (5-8C), or is a branched-chain (.omega.-1)-hydroxyalkyl (5-8C), or is an (.omega.-1)-oxoalkyl (5-8C), or is an (.omega., .omega.-1) or (.omega.-1, .omega.-2)-dihydroxyalkyl (5-8C), or is an alkenyl substituent (5-8C), and the other is alkyl (1-12C) optionally containing one or two non-adjacent oxygen atoms in place of C.Type: GrantFiled: January 25, 1995Date of Patent: December 17, 1996Assignee: Fred Hutchinson Cancer Research CenterInventors: James A. Bianco, Stuart L. Bursten, Jack W. Singer